Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03382639 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia
A Phase 2 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 256
- Enrollment target
NCT03382639 is a Phase 2 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 256 participants.
The verdict
NCT03382639, a Phase 2 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 256 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether add-on luvadaxistat is superior to placebo on the Positive and Negative Syndrome Scale Negative Symptom Factor Score (PANSS NSFS).
Interventions
- DRUG Placebo
- DRUG Luvadaxistat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2018-01-04 |
| Est. Completion | 2021-01-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03382639
The ClinicalTrials.gov registry entry for NCT03382639 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03382639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03382639 about?
NCT03382639 is a clinical study titled "A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia". The purpose of this study is to determine whether add-on luvadaxistat is superior to placebo on the Positive and Negative Syndrome Scale Negative Symptom Factor Score (PANSS NSFS).
What is the current status of trial NCT03382639?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2018-01-04. Estimated completion is 2021-01-12.
What interventions are being tested in trial NCT03382639?
The interventions under investigation include: Placebo (DRUG), Luvadaxistat (DRUG).
Who is sponsoring clinical trial NCT03382639?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.